By Chris Wack

Precigen shares were up 6%, to $3.32, in premarket trading after the company said it saw positive long-term follow-up data for Papzimeos for treatment of adults with recurrent respiratory papillomatosis.

Papzimeos was granted full approval by the Food and Drug Administration in August.

The biopharmaceutical company said Papzimeos approval was supported by results from a study that met its primary safety and pre-specified primary efficacy endpoints. Papzimeos was well tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than Grade 2.

The Germantown, Md., company said 51%, or 18 out of 35, of study patients achieved complete response, requiring no surgeries in the 12-month period after treatment with Papzimeos.

Precigen said prolonged reduction in the requirement for surgical intervention to manage RRP was observed throughout long-term follow-up of evaluable study patients compared to the year prior to treatment.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

October 13, 2025 07:54 ET (11:54 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.